Pak C Y
J Clin Pharmacol. 1979 Aug-Sep;19(8-9 Pt 1):451-7. doi: 10.1002/j.1552-4604.1979.tb02507.x.
The safety and effectiveness of sodium cellulose phosphate (SCP) in the treatment of calcium urolithiasis of absorptive hypercalciuria was explored. Eighteen patients with absorptive hypercalciuria with intestinal hyperabsorption of calcium, normal or suppressed parathyroid function, and active stone disease received 10 to 15 Gm SCP daily (2.5 to 5 Gm with meals) and 2 to 3 Gm magnesium gluconate daily (1 to 1.5 Gm twice daily orally separately from SCP) for eight to 54 months, while maintained on a moderate calcium and oxalate restriction. During treatment, serum calcium, immunoreactive parathyroid hormone, and urinary cyclic AMP remained within the normal range. Serum alkaline phosphatase and bone density (measured by photon absorptiometry) did not change significantly or remained within normal limits. Serum concentrations of magnesium, copper, zinc, and iron and blood hematocrit were not significantly altered by therapy. However, urinary calcium returned toward normal, and incidence of renal stone formation markedly decreased. The results suggest that SCP is a safe and an effective drug for absorptive hypercalciuria.
探讨了磷酸纤维素钠（SCP）治疗吸收性高钙尿症所致钙性尿路结石的安全性和有效性。18例吸收性高钙尿症患者，伴有肠道钙吸收增加、甲状旁腺功能正常或受抑制以及活动性结石病，每日接受10至15克SCP（每餐2.5至5克）和每日2至3克葡萄糖酸镁（每日1至1.5克，分两次口服，与SCP分开），持续8至54个月，同时维持适度的钙和草酸盐限制。治疗期间，血清钙、免疫反应性甲状旁腺激素和尿环磷酸腺苷保持在正常范围内。血清碱性磷酸酶和骨密度（通过光子吸收法测量）无显著变化或保持在正常范围内。治疗未显著改变血清镁、铜、锌、铁浓度及血细胞比容。然而，尿钙恢复正常，肾结石形成的发生率显著降低。结果表明，SCP是治疗吸收性高钙尿症的一种安全有效的药物。
